Lilly pays Sitryx $50M upfront for preclinical autoimmune assets

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Mar 31, 2020 at 11:22 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,741
    Likes Received:
    3
    via Eli Lilly has paid Sitryx $50 million (€46 million) upfront for global rights to up to four autoimmune drugs. The deal sees Lilly commit to up to $820 million in development milestones for the chance to work with Sitryx on drugs that manipulate intracellular metabolic pathways.

    article source